Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
- DOI
- 10.1016/s2213-2600(20)30515-4
- Published
- 2021-06
- Container
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-2600-20-30515-4,
title = {Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study},
author = {Timothy A Yap and Kazuhiko Nakagawa and Nobukazu Fujimoto and Kozo Kuribayashi and Tormod Kyrre Guren and Luana Calabrò and Ronnie Shapira-Frommer and Bo Gao and Steven Kao and Ignacio Matos and David Planchard and Arkendu Chatterjee and Fan Jin and Kevin Norwood and Hedy L Kindler},
year = {2021},
journal = {The Lancet Respiratory Medicine},
doi = {10.1016/s2213-2600(20)30515-4},
url = {https://doi.org/10.1016/s2213-2600(20)30515-4}
}RIS
TY - JOUR TI - Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study AU - Timothy A Yap AU - Kazuhiko Nakagawa AU - Nobukazu Fujimoto AU - Kozo Kuribayashi AU - Tormod Kyrre Guren AU - Luana Calabrò AU - Ronnie Shapira-Frommer AU - Bo Gao AU - Steven Kao AU - Ignacio Matos AU - David Planchard AU - Arkendu Chatterjee AU - Fan Jin AU - Kevin Norwood AU - Hedy L Kindler PY - 2021 JO - The Lancet Respiratory Medicine DO - 10.1016/s2213-2600(20)30515-4 UR - https://doi.org/10.1016/s2213-2600(20)30515-4 ER -
APA
Yap, T. A., Nakagawa, K., Fujimoto, N., Kuribayashi, K., Guren, T. K., Calabrò, L., Shapira-Frommer, R., Gao, B., Kao, S., Matos, I., Planchard, D., Chatterjee, A., Jin, F., Norwood, K., & Kindler, H. L. (2021). Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(20)30515-4
Source records
- crossref · retrieved 2026-09-27T00:46:34.081Z